CA3078238A1 - Methods of treating bacterial infections - Google Patents

Methods of treating bacterial infections Download PDF

Info

Publication number
CA3078238A1
CA3078238A1 CA3078238A CA3078238A CA3078238A1 CA 3078238 A1 CA3078238 A1 CA 3078238A1 CA 3078238 A CA3078238 A CA 3078238A CA 3078238 A CA3078238 A CA 3078238A CA 3078238 A1 CA3078238 A1 CA 3078238A1
Authority
CA
Canada
Prior art keywords
subject
vaborbactam
meropenem
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3078238A
Other languages
English (en)
French (fr)
Inventor
Elizabeth Alexander
Jeff Loutit
Michael N. Dudley
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65994826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3078238(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of CA3078238A1 publication Critical patent/CA3078238A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3078238A 2017-10-03 2018-10-01 Methods of treating bacterial infections Pending CA3078238A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762567702P 2017-10-03 2017-10-03
US62/567,702 2017-10-03
US201862657402P 2018-04-13 2018-04-13
US62/657,402 2018-04-13
PCT/US2018/053772 WO2019070591A1 (en) 2017-10-03 2018-10-01 METHODS OF TREATING BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
CA3078238A1 true CA3078238A1 (en) 2019-04-11

Family

ID=65994826

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3078238A Pending CA3078238A1 (en) 2017-10-03 2018-10-01 Methods of treating bacterial infections

Country Status (16)

Country Link
US (3) US11376237B2 (cg-RX-API-DMAC7.html)
EP (1) EP3691652A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020536092A (cg-RX-API-DMAC7.html)
KR (1) KR20200066664A (cg-RX-API-DMAC7.html)
CN (1) CN111432821A (cg-RX-API-DMAC7.html)
AU (1) AU2018345317B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020006658A2 (cg-RX-API-DMAC7.html)
CA (1) CA3078238A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000892A1 (cg-RX-API-DMAC7.html)
JO (1) JOP20200075A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020003670A (cg-RX-API-DMAC7.html)
MY (1) MY200934A (cg-RX-API-DMAC7.html)
PH (1) PH12020550249A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202003009QA (cg-RX-API-DMAC7.html)
TW (2) TW202400146A (cg-RX-API-DMAC7.html)
WO (1) WO2019070591A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018345317B2 (en) * 2017-10-03 2024-10-24 Melinta Therapeutics, Inc. Methods of treating bacterial infections
EP4313033A4 (en) * 2021-03-24 2025-04-23 Trustees Of Tufts College BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912363A (zh) 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
CN102188395B (zh) 2011-04-29 2012-12-05 石药集团中诺药业（石家庄）有限公司 一种更稳定的美罗培南注射剂及其制备方法
CN102335137B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种含美罗培南的药物组合物
CN102335136B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种供注射用美罗培南药物组合物及其制备方法
CN102525961B (zh) 2012-01-17 2013-02-13 山东罗欣药业股份有限公司 美罗培南组合物注射用粉针剂
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN103570718B (zh) 2012-07-31 2016-06-29 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
RU2675847C2 (ru) 2013-05-28 2018-12-25 Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми Комбинированные терапевтические средства, содержащие оксазолидинон-хинолоны, предназначенные для лечения бактериальных инфекций
WO2016172208A1 (en) * 2015-04-24 2016-10-27 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
EP3319609B1 (en) 2015-07-09 2022-06-15 Washington University Compositions and methods of use of antibacterial drug combinations
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
US12478606B2 (en) 2017-01-09 2025-11-25 Melinta Subsidiary Corp. Methods of treating bacterial infections
AU2018345317B2 (en) 2017-10-03 2024-10-24 Melinta Therapeutics, Inc. Methods of treating bacterial infections

Also Published As

Publication number Publication date
SG11202003009QA (en) 2020-04-29
EP3691652A1 (en) 2020-08-12
TW201922241A (zh) 2019-06-16
US20260102374A1 (en) 2026-04-16
AU2018345317B2 (en) 2024-10-24
MY200934A (en) 2024-01-24
US20200297695A1 (en) 2020-09-24
US20220288024A1 (en) 2022-09-15
MX2020003670A (es) 2020-08-03
US11376237B2 (en) 2022-07-05
JP2020536092A (ja) 2020-12-10
KR20200066664A (ko) 2020-06-10
WO2019070591A1 (en) 2019-04-11
JOP20200075A1 (ar) 2020-04-30
EP3691652A4 (en) 2021-07-07
CN111432821A (zh) 2020-07-17
TW202400146A (zh) 2024-01-01
AU2018345317A1 (en) 2020-05-07
PH12020550249A1 (en) 2021-02-15
CL2020000892A1 (es) 2020-10-23
US12533342B2 (en) 2026-01-27
BR112020006658A2 (pt) 2020-09-24

Similar Documents

Publication Publication Date Title
US20260102374A1 (en) Methods of treating bacterial infections
US20250325522A1 (en) Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
CA2764587C (en) Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
US20090226393A1 (en) Polymer paclitaxel conjugates and methods for treating cancer
US20260097005A1 (en) Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions
AU2020275208A1 (en) Formulation of delgocitinib in the form of a cream
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
US12629353B2 (en) Use of composition in treatment of cerebral stroke
CA3071096A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury
US20210052608A1 (en) Methods of treating bacterial infections with minocycline
AU2024343419A1 (en) Sparsentan for treating immunoglobulin a nephropathy (igan)
HK40092749A (en) Use of composition in treatment of cerebral stroke
HK40059411B (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
HK40012204A (en) Treatment of inflammation using l-ornithine phenylacetate
HK1203419B (en) Treatment of brain inflammation using l-ornithine phenylacetate

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240903

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250903

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260401